Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
deal
Pharma
England's Abcam weighs its options, which could include a sale
After Abcam quit its £270 million bid for Horizon Discovery in 2018, the antibody expert may have found itself on the opposite end of the M&A table.
Fraiser Kansteiner
Jun 29, 2023 8:05am
Sanofi is offloading 17 meds from its pain and CNS rosters
Jul 12, 2022 9:13am
Collaboration in biopharma is 'alive and well,' panel says
Jan 19, 2022 11:15am
Novartis launches $15B share buyback campaign
Dec 16, 2021 10:20am
Large pharmas will have $1.7T M&A firepower next year: analyst
Dec 1, 2021 11:05am
Pharma deal values plummet 56% due to COVID-19: report
Jul 23, 2020 3:30pm